Join
Live feed
·
PRReleasevia Quantisnow
Actuate Therapeutics Inc. logo

Actuate Therapeutics Announces Nature Medicine Publication of Clinical Trial Results Showing Doubling of the Rate of Survival with Elraglusib Plus Chemotherapy in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma

ByQuantisnow·Wall Street's wire, on your screen.
ACTU· Actuate Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ACTU (Actuate Therapeutics Inc.) and more on Quantisnow.